An Insight Into Commercially Available SGLT2 Inhibitors and Their Structure–Activity Relationship Studies
Archiv der Pharmazie · 2025-10 · 358 (10)
DOI: 10.1002/ardp.70127 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archiv der Pharmazie, online erschienen am 24.10.2025. Verfasst von Asiya Parveen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Hypoglycemic Agents, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 152 Literaturangaben. Gefördert von: Department of Science and Technology, Ministry of Science and Technology, India., Department of Science and Technology, Ministry of Science and Technology, India.
Abstract (Originalsprache)
A serious, rapidly growing global health issue is diabetes mellitus (Type 2) caused by insulin deficiency or insulin resistance. This is a chronic condition that demands ongoing care and management. Although a variety of anti‐hyperglycaemic medications are available, the need for safer, more effective, and affordable antidiabetic treatments remains crucial due to the undesirable side effects associated with existing options. This review primarily highlights the innovative sodium‐glucose co‐transporter 2 (SGLT‐2) inhibitors and explores their various characteristics. Gliflozins represent an important class of medications used to manage type II diabetes by targeting the SGLT2. By inhibiting SGLT2, they effectively reduce blood glucose levels by preventing the kidneys from reabsorbing glucose. This review offers a comprehensive overview of gliflozins approved by leading regulatory authorities such as the Food and Drug Administration (FDA), European Medicines Agency (EMA), and Pharmaceuticals and Medical Devices Agency (PMDA). It explores the design and development of sodium‐glucose co‐transporter (SGLT) inhibitors, their mechanisms of action, structure–activity relationships, and additional therapeutic applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
- Department of Pharmaceutical Biotechnology, School of Pharmaceutical Education and Research, New Delhi, India.
ORCID-Profile: Syed Ali Hasnain Zaidi, M Shahar Yar
Förderung
- Department of Science and Technology, Ministry of Science and Technology, India.
- Department of Science and Technology, Ministry of Science and Technology, India
Zitieren
APA
Parveen, A., Parveen, S., Vats, N., Shafeeque, M., Choudhary, A., Zaidi, S. A. H., & Yar, M. S. (2025). An Insight Into Commercially Available SGLT2 Inhibitors and Their Structure–Activity Relationship Studies. Archiv der Pharmazie, 358(10). https://doi.org/10.1002/ardp.70127
Vancouver
Parveen A, Parveen S, Vats N, Shafeeque M, Choudhary A, Zaidi SAH, et al. An Insight Into Commercially Available SGLT2 Inhibitors and Their Structure–Activity Relationship Studies. Archiv der Pharmazie. 2025;358(10). doi:10.1002/ardp.70127
BibTeX
@article{Parveen2025,
author = {Parveen, Asiya and Parveen, Shazia and Vats, Nisha and Shafeeque, Mohd and Choudhary, Akram and Zaidi, Syed Ali Hasnain and Yar, M Shahar},
title = {An Insight Into Commercially Available SGLT2 Inhibitors and Their Structure–Activity Relationship Studies},
journal = {Archiv der Pharmazie},
year = {2025},
volume = {358},
number = {10},
doi = {10.1002/ardp.70127}
}
EUVIMED